Software Transparency Is No Longer Optional for Medical Device Makers
If you build medical device software or life sciences platforms, you have watched the regulatory ground shift under a specific expectation over the past several years: regulators want to know what is inside your software, in a structured, machine-readable format, and they want a real process behind vulnerability disclosure when something is found in a component you shipped. This is not a distant policy discussion. It shows up in premarket submissions, in postmarket surveillance expectations, and increasingly in the questions your own customers, hospital systems and health networks, ask before they will purchase or renew.
The practical difficulty is that most medtech and life sciences engineering teams were not built around software supply chain transparency as a first-class discipline. Device software often has a long lifecycle, incorporates third-party and open source components accumulated over years of development, and was frequently built before anyone on the team was asked to produce a software bill of materials for it. Retrofitting that transparency, and then keeping it current as new vulnerabilities are disclosed against components already shipped in devices in the field, is a real operational burden, not a one-time documentation exercise.
SBOM generation built for the requirement, not just the audit
Safeguard's SBOM generation and analysis produces software bills of materials in both SPDX and CycloneDX formats, with more than 30 export options [GA]. That format flexibility matters in this sector specifically, because different regulatory submissions, different customer questionnaires, and different downstream tools expect different formats, and re-generating an SBOM by hand for each audience is exactly the kind of manual work that does not scale as your product portfolio grows.
Just as important is what sits underneath the SBOM: full transitive dependency inventory and deep dependency scanning [GA], reaching the layers of open source and third-party components that a shallow, top-level dependency list would miss entirely. For a device with a years-long support lifecycle, that depth is what makes the SBOM useful years after the initial release, when a vulnerability is disclosed in a package three layers down that nobody on the current team remembers including.
Vulnerability disclosure and the CSAF and VEX workflow
The regulatory expectation around medical device software increasingly extends past the SBOM itself into how you communicate vulnerability status once something is found. Safeguard supports CSAF and VEX upload [GA], the structured formats that let a vendor state, in a machine-readable way, whether a known vulnerability in a component actually affects a given product. This distinction, a vulnerability existing in a component versus a vulnerability being exploitable in your specific product configuration, is exactly what reachability analysis is built to help establish [GA], cutting through a noisy CVE list to identify what genuinely needs a disclosure and what does not.
Attestation and signing, covering SLSA, Sigstore, and in-toto, along with SCAL and LCAL scoring [GA], adds a further layer of provenance to that story: not just what is in the software, but verifiable evidence of how it was built and whether it has been tampered with along the way, which matters when a regulator or a hospital procurement team is evaluating trust in your supply chain rather than just your product's features.
Compliance automation across the broader GRC picture
SBOMs and disclosure are one piece of a larger compliance posture. Safeguard's compliance and GRC suite covers frameworks, controls, evidence collection, continuous monitoring, and questionnaire response across 373 frameworks, spanning government regulation, industry standards, and internal policy [GA], with compliance automation and auditing built into the same platform [GA]. For a medtech engineering or quality team that does not have the headcount to run manual evidence collection across every framework a customer or regulator might invoke, automated, continuous evidence generation is the difference between compliance being a recurring fire drill and being a standing, always-current answer.
License compliance as a quieter but real risk
Life sciences and medtech software also carries license risk that is easy to overlook under the pressure of vulnerability and regulatory concerns. License compliance checking against SPDX data and organizational policy [GA] flags obligations, copyleft terms in particular, that can create real constraints on how a device's software can be distributed or modified, a risk that becomes expensive to discover only after a product has shipped.
Where this leaves your team
The direction of regulatory travel in medtech is toward more software transparency, not less, and toward real vulnerability disclosure processes rather than static documentation produced once at launch. Building that discipline into your development lifecycle now, with SBOM generation, reachability-prioritized vulnerability management, structured disclosure through CSAF and VEX, and continuous compliance evidence, puts you ahead of a requirement that is only going to tighten.
If your team is building medical device or life sciences software and needs a clearer path to software transparency and compliance automation that keeps pace with your regulatory obligations, visit safeguard.sh to see how the platform fits into your existing development and quality processes.
